Melanoma other imaging findings

	Melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Genetic Counselling
Cost-Effectiveness of Therapy
Future or Investigational Therapies
2019 AAD Guidelines for management of Primary Cutaneous Melanoma (CM)
Guidelines for Diagnosis of Primary CM
Guidelines for Treatment of Primary CM
Guidelines for management of Primary CM in Pregnancy
Case Studies
Case #1
Melanoma other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Melanoma other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Melanoma other imaging findings
CDC on Melanoma other imaging findings
Melanoma other imaging findings in the news
Blogs on Melanoma other imaging findings
Directions to Hospitals Treating Melanoma
Risk calculators and risk factors for Melanoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview[edit | edit source]

Dynamic contrast-enhanced MRI (DCE-MRI), positron emission tomography (PET) scan, and Integrated ¹⁸F-FDG PET/CT can be used during the diagnostic process of melanoma. DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease. Integrated ¹⁸F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis. Positron emission tomography (PET) scan can help in diagnosing metastatic lesions.

Dynamic contrast-enhanced MRI[edit | edit source]

Dynamic contrast-enhanced MRI can reveal different contrast enhancement patterns in relation to microvasculature and the expression of angiogenetic factor such as vascular endothelial growth factor.^[1]
It can differentiate the tumor characterization between metastatic and non-metastatic melanoma by the K^trans value.^[2]^[1]
DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease.^[2]

Positron Emission Tomography (PET) Scan[edit | edit source]

Chest PET scan may be considered for diagnosis of metastatic lesions in the following conditions:^[3]

For patients who have been diagnosed with stage IA-IV melanoma
For secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years)

Integrated ¹⁸F-FDG PET/CT[edit | edit source]

Integrated ¹⁸F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis.^[4]

References[edit | edit source]

↑ ^1.0 ^1.1 Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK (May 2012). "Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts". Int. J. Radiat. Oncol. Biol. Phys. 83 (1): e121–7. doi:10.1016/j.ijrobp.2011.12.019. PMID 22381901.
↑ ^2.0 ^2.1 Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV (2017). "Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential". J Comput Assist Tomogr. 41 (5): 823–827. doi:10.1097/RCT.0000000000000598. PMID 28448404.
↑ Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.
↑ Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.

Template:WikiDoc Sources

[pmid22381901-1] 1.0 ^1.1 Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK (May 2012). "Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts". Int. J. Radiat. Oncol. Biol. Phys. 83 (1): e121–7. doi:10.1016/j.ijrobp.2011.12.019. PMID 22381901.

[pmid28448404-2] 2.0 ^2.1 Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV (2017). "Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential". J Comput Assist Tomogr. 41 (5): 823–827. doi:10.1097/RCT.0000000000000598. PMID 28448404.

[pmid23584343-3] Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.

[pmid26204273-4] Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.

[1]

[2]

[3]